Key clinical point: Clinicians need to monitor carefully for mucocutaneous squamous cell carcinoma (SCC) in epidermolysis bullosa (EB).

Major finding: The median survival after a first diagnosis of SCC was 2.4 years, in patients with generalized severe recessive dystrophic EB.

Study details: An observational, retrospective case record review of 44 patients with EB who were diagnosed with SCC over a 28-year study period.

Disclosures: The study had no commercial funding. Dr. Mellerio disclosed financial relationships with Castle Creek Pharmaceuticals and ProQR Therapeutics, and acted as an unpaid advisor to Helpberby Therapeutics. Dr. South disclosed financial relationships with Krystal Biotech Inc. and Amryt Genetics and has been an advisory board member for Abeona Therapeutics and Sanofi Genzyme. Dr. Bruckner-Tuderman disclosed receiving grants or research support from Constant Pharmaceuticals/Tarix Orphan.